Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum

Neuroscience

Volumn 155, Issue 4, 2008, Pages 1174-1194

  Pattarini, R ^a   Rong, Y ^a   Qu, C ^a   Morgan, J I ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Affymetrix array; B6.129X1 Baxtm1Sjk J mice; C57BL 6J mice; Parkinson's disease; Swiss Webster mice

Indexed keywords

1 METHYL 4 PHENYL 1,2,3,6 TETRAHYDROPYRIMIDINE; MESSENGER RNA; NEUROTOXIN; PROTEIN BAX; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MAPPING; C57BL 6 MOUSE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SWISS WEBSTER MOUSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CHROMOSOME MAPPING; CORPUS STRIATUM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROARRAY ANALYSIS; NEUROTOXINS; TIME FACTORS;

EID: 50649106636     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.06.064     Document Type: Article

References (150)

1. Abeliovich A. Parkinson's disease: pro-survival effects of PINK1. Nature 448 (2007) 759-760
2. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Castillo P.E., Shinsky N., Verdugo J.M., Armanini M., Ryan A., Hynes M., Phillips H., Sulzer D., and Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25 (2000) 239-252
3. Agani F.H., Pichiule P., Chavez J.C., and LaManna J.C. The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia. J Biol Chem 275 (2000) 35863-35867
4. Ahn T.B., Kim S.Y., Kim J.Y., Park S.S., Lee D.S., Min H.J., Kim Y.K., Kim S.E., Kim J.M., Kim H.J., Cho J., and Jeon B.S. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 70 (2008) 43-49
5. Albanese A., Valente E.M., Romito L.M., Bellacchio E., Elia A.E., and Dallapiccola B. The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease. Neurology 64 (2005) 1958-1960
6. Arima K., Hirai S., Sunohara N., Aoto K., Izumiyama Y., Ueda K., Ikeda K., and Kawai M. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies. Brain Res 843 (1999) 53-61
7. Bassuk A.G., and Leiden J.M. A direct physical association between ETS and AP-1 transcription factors in normal human T cells. Immunity 3 (1995) 223-237
8. Bates T.E., Heales S.J., Davies S.E., Boakye P., and Clark J.B. Effects of 1-methyl-4-phenylpyridinium on isolated rat brain mitochondria: evidence for a primary involvement of energy depletion. J Neurochem 63 (1994) 640-648
9. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 991 (2003) 120-131
10. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 57 (1995) 289-300
11. Benmoyal-Segal L., and Soreq H. Gene-environment interactions in sporadic Parkinson's disease. J Neurochem 97 (2006) 1740-1755
12. Bianchi R., Pula G., Ceccarelli P., Giambanco I., and Donato R. S-100 protein binds to annexin II and p11, the heavy and light chains of calpactin I. Biochim Biophys Acta 1160 (1992) 67-75
13. Bonifati V., Rohe C.F., Breedveld G.J., Fabrizio E., De Mari M., Tassorelli C., Tavella A., Marconi R., Nicholl D.J., Chien H.F., Fincati E., Abbruzzese G., Marini P., De Gaetano A., Horstink M.W., Maat-Kievit J.A., Sampaio C., Antonini A., Stocchi F., Montagna P., Toni V., Guidi M., Dalla Libera A., Tinazzi M., De Pandis F., Fabbrini G., Goldwurm S., de Klein A., Barbosa E., Lopiano L., Martignoni E., Lamberti P., Vanacore N., Meco G., and Oostra B.A. Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology 65 (2005) 87-95
14. Boyd J.D., Jang H., Shepherd K.R., Faherty C., Slack S., Jiao Y., and Smeyne R.J. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta. Brain Res 1175 (2007) 107-116
15. Bradbury A.J., Costall B., Jenner P.G., Kelly M.E., Marsden C.D., and Naylor R.J. MPP+ can disrupt the nigrostriatal dopamine system by acting in the terminal area. Neuropharmacology 25 (1986) 939-941
16. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., and Levy L.S. Pesticides and Parkinson's disease: is there a link?. Environ Health Perspect 114 (2006) 156-164
17. Butte A. The use and analysis of microarray data. Nat Rev Drug Discov 1 (2002) 951-960
18. Cadet J.L., Jayanthi S., McCoy M.T., Vawter M., and Ladenheim B. Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse 41 (2001) 40-48
19. Carra S., Seguin S.J., Lambert H., and Landry J. HSPB8 chaperone activity towards poly-Q containing proteins depends on its association with BAG3, a stimulator of macroautophagy. J Biol Chem 283 (2008) 1437-1444
20. Chen J.Y., Hsu P.C., Hsu I.L., and Yeh G.C. Sequential up-regulation of the c-fos, c-jun and bax genes in the cortex, striatum and cerebellum induced by a single injection of a low dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57BL/6 mice. Neurosci Lett 314 (2001) 49-52
21. Chiba-Falek O., Lopez G.J., and Nussbaum R.L. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord 21 (2006) 1703-1708
22. Chiba K., Trevor A.J., and Castagnoli Jr. N. Active uptake of MPP+, a metabolite of MPTP, by brain synaptosomes. Biochem Biophys Res Commun 128 (1985) 1228-1232
23. Chin M.H., Qian W.J., Wang H., Petyuk V.A., Bloom J.S., Sforza D.M., Lacan G., Liu D., Khan A.H., Cantor R.M., Bigelow D.J., Melega W.P., Camp II D.G., Smith R.D., and Smith D.J. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J Proteome Res 7 (2008) 666-677
24. Cook R., Lu L., Gu J., Williams R.W., and Smeyne R.J. Identification of a single QTL, Mptp1, for susceptibility to MPTP-induced substantia nigra pars compacta neuron loss in mice. Brain Res Brain Res Rev 110 (2003) 279-288
25. Cookson M.R. The biochemistry of Parkinson's disease. Annu Rev Biochem 74 (2005) 29-52
26. Costoya J.A. Functional analysis of the role of POK transcriptional repressors. Brief Funct Genomic Proteomic 6 (2007) 8-18
27. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
28. de Kloet E.R., Sibug R.M., Helmerhorst F.M., and Schmidt M.V. Stress, genes and the mechanism of programming the brain for later life. Neurosci Biobehav Rev 29 (2005) 271-281
29. Doucet J.P., Nakabeppu Y., Bedard P.J., Hope B.T., Nestler E.J., Jasmin B.J., Chen J.S., Iadarola M.J., St-Jean M., Wigle N., Blanchet P., Grondin R., and Robertson G.S. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein (s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996) 365-381
30. Duchemin A.M., Gudehithlu K.P., Neff N.H., and Hadjiconstantinou M. c-fos mRNA in mouse brain after MPTP treatment. Neurochem Int 20 (1992) 281-287
31. Eberling J.L., Bankiewicz K.S., Jordan S., VanBrocklin H.F., and Jagust W.J. PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport 8 (1997) 2727-2733
32. Edwards M.G., Sarkar D., Klopp R., Morrow J.D., Weindruch R., and Prolla T.A. Impairment of the transcriptional responses to oxidative stress in the heart of aged C57BL/6 mice. Ann N Y Acad Sci 1019 (2004) 85-95
33. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev 7 (2006) 306-318
34. Fernandez-Gonzalez A., Perez-Otano I., and Morgan J.I. MPTP selectively induces haem oxygenase-1 expression in striatal astrocytes. Eur J Neurosci 12 (2000) 1573-1583
35. Francis J.W., Von Visger J., Markelonis G.J., and Oh T.H. Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. Neurotoxicol Teratol 17 (1995) 7-12
36. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69 (1997) 1322-1325
37. Gallant S., and Gilkeson G. ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp 54 (2006) 149-163
38. German D.C., Nelson E.L., Liang C.L., Speciale S.G., Sinton C.M., and Sonsalla P.K. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration 5 (1996) 299-312
39. Grigoryev D.N., Liu M., Cheadle C., Barnes K.C., and Rabb H. Genomic profiling of kidney ischemia-reperfusion reveals expression of specific alloimmunity-associated genes: Linking "immune" and "nonimmune" injury events. Transplant Proc 38 (2006) 3333-3336
40. Grottick A.J., Bagnol D., Phillips S., McDonald J., Behan D.P., Chalmers D.T., and Hakak Y. Neurotransmission- and cellular stress-related gene expression associated with prepulse inhibition in mice. Brain Res Brain Res Rev 139 (2005) 153-162
41. Grunblatt E., Mandel S., Maor G., and Youdim M.B. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem 78 (2001) 1-12
42. Gureviciene I., Gurevicius K., and Tanila H. Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis 28 (2007) 83-89
43. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp Neurol 193 (2005) 279-290
44. Hald A., Van Beek J., and Lotharius J. Inflammation in Parkinson's disease: causative or epiphenomenal?. Subcell Biochem 42 (2007) 249-279
45. Hamre K., Tharp R., Poon K., Xiong X., and Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: quantitative analysis in seven strains of Mus musculus. Brain Res Brain Res Rev 828 (1999) 91-103
46. Haque M.E., Thomas K.J., D'Souza C., Callaghan S., Kitada T., Slack R.S., Fraser P., Cookson M.R., Tandon A., and Park D.S. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci U S A (2008) in press
47. Hardy R.J., and Friedrich Jr. V.L. Progressive remodeling of the oligodendrocyte process arbor during myelinogenesis. Dev Neurosci 18 (1996) 243-254
48. Hasegawa E., Asagami H., Kang D., Minakami S., and Takeshige K. 1-Methyl-4-phenylpyridinium (MPP+) inhibits mitochondrial oxygen consumption mediated by succinate as well as malate in rat pheochromocytoma PC12 cells. Biochem Mol Biol Int 35 (1995) 409-413
49. Hebert G., Arsaut J., Dantzer R., and Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 349 (2003) 191-195
50. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., and Johannessen J.N. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40 (1991) 133-158
51. Hershenson M.B. p21Waf1/Cip1 and the prevention of oxidative stress. Am J Physiol 286 (2004) L502-L505
52. Huang Y., Cheung L., Rowe D., and Halliday G. Genetic contributions to Parkinson's disease. Brain Res 46 (2004) 44-70
53. Hunot S., Vila M., Teismann P., Davis R.J., Hirsch E.C., Przedborski S., Rakic P., and Flavell R.A. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 665-670
54. Hunter R.L., Dragicevic N., Seifert K., Choi D.Y., Liu M., Kim H.C., Cass W.A., Sullivan P.G., and Bing G. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100 (2007) 1375-1386
55. Imai Y., Inoue H., Kataoka A., Hua-Qin W., Masuda M., Ikeda T., Tsukita K., Soda M., Kodama T., Fuwa T., Honda Y., Kaneko S., Matsumoto S., Wakamatsu K., Ito S., Miura M., Aosaki T., Itohara S., and Takahashi R. Pael receptor is involved in dopamine metabolism in the nigrostriatal system. Neurosci Res 59 (2007) 413-425
56. Imai Y., Soda M., Murakami T., Shoji M., Abe K., and Takahashi R. A product of the human gene adjacent to parkin is a component of Lewy bodies and suppresses Pael receptor-induced cell death. J Biol Chem 278 (2003) 51901-51910
57. Ishizawa T., Mattila P., Davies P., Wang D., and Dickson D.W. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 62 (2003) 389-397
58. Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., and Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Brain Res Rev 57 (1998) 1-9
59. Iwamoto R., Higashiyama S., Mitamura T., Taniguchi N., Klagsbrun M., and Mekada E. Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity. EMBO J 13 (1994) 2322-2330
60. Jackson-Lewis V., Jakowec M., Burke R.E., and Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4 (1995) 257-269
61. Jackson-Lewis V., and Smeyne R.J. MPTP and SNpc DA neuronal vulnerability: role of dopamine, superoxide and nitric oxide in neurotoxicity. Minireview. Neurotox Res 7 (2005) 193-202
62. Jakes R., Spillantini M.G., and Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett 345 (1994) 27-32
63. Jakovcevski I., and Zecevic N. Sequence of oligodendrocyte development in the human fetal telencephalon. Glia 49 (2005) 480-491
64. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 82 (1985) 2173-2177
65. Kawaguchi Y., Wilson C.J., Augood S.J., and Emson P.C. Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci 18 (1995) 527-535
66. Kindt M.V., Heikkila R.E., and Nicklas W.J. Mitochondrial and metabolic toxicity of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine. J Pharmacol Exp Ther 242 (1987) 858-863
67. Kingsbury A.E., Daniel S.E., Sangha H., Eisen S., Lees A.J., and Foster O.J. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov Disord 19 (2004) 162-170
68. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
69. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., and Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104 (2007) 11441-11446
70. Kitao Y., Imai Y., Ozawa K., Kataoka A., Ikeda T., Soda M., Nakimawa K., Kiyama H., Stern D.M., Hori O., Wakamatsu K., Ito S., Itohara S., Takahashi R., and Ogawa S. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16 (2007) 50-60
71. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
72. Krueger M.J., Singer T.P., Casida J.E., and Ramsay R.R. Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone. Biochem Biophys Res Commun 169 (1990) 123-128
73. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998) 106-108
74. Kuhn K., Wellen J., Link N., Maskri L., Lubbert H., and Stichel C.C. The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci 17 (2003) 1-12
75. Ladeby R., Wirenfeldt M., Dalmau I., Gregersen R., Garcia-Ovejero D., Babcock A., Owens T., and Finsen B. Proliferating resident microglia express the stem cell antigen CD34 in response to acute neural injury. Glia 50 (2005) 121-131
76. Landrigan P.J., Sonawane B., Butler R.N., Trasande L., Callan R., and Droller D. Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect 113 (2005) 1230-1233
77. Leung Y.F., Tam P.O., Lee W.S., Lam D.S., Yam H.F., Fan B.J., Tham C.C., Chua J.K., and Pang C.P. The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells. Mol Vision 9 (2003) 425-439
78. Li J.Y., Henning Jensen P., and Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience 113 (2002) 463-478
79. Li X.J., Li S.H., Sharp A.H., Nucifora Jr. F.C., Schilling G., Lanahan A., Worley P., Snyder S.H., and Ross C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378 (1995) 398-402
80. Linder J.C., Young S.J., and Groves P.M. Electron microscopic evidence for neurotoxicity in the basal ganglia. Neurochem Int 26 (1995) 195-202
81. Liu P.K., Grossman R.G., Hsu C.Y., and Robertson C.S. Ischemic injury and faulty gene transcripts in the brain. Trends Neurosci 24 (2001) 581-588
82. Malagelada C., Ryu E.J., Biswas S.C., Jackson-Lewis V., and Greene L.A. RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation. J Neurosci 26 (2006) 9996-10005
83. Mandel S., Grunblatt E., Maor G., and Youdim M.B. Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res 27 (2002) 1231-1243
84. Marazziti D., Gallo A., Golini E., Matteoni R., and Tocchini-Valentini G.P. Molecular cloning and chromosomal localization of the mouse Gpr37 gene encoding an orphan G-protein-coupled peptide receptor expressed in brain and testis. Genomics 53 (1998) 315-324
85. Marazziti D., Golini E., Gallo A., Lombardi M.S., Matteoni R., and Tocchini-Valentini G.P. Cloning of GPR37, a gene located on chromosome 7 encoding a putative G-protein-coupled peptide receptor, from a human frontal brain EST library. Genomics 45 (1997) 68-77
86. Marin O., Anderson S.A., and Rubenstein J.L. Origin and molecular specification of striatal interneurons. J Neurosci 20 (2000) 6063-6076
87. McClintick J.N., and Edenberg H.J. Effects of filtering by Present call on analysis of microarray experiments. BMC Bioinformat 7 (2006) 49
88. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
89. McGeer P.L., and McGeer E.G. Glial reactions in Parkinson's disease. Mov Disord (2007) in press
90. Mead R.J., Neal J.W., Griffiths M.R., Linington C., Botto M., Lassmann H., and Morgan B.P. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest 84 (2004) 21-28
91. Miller R.M., Chen L.L., Kiser G.L., Giesler T.L., Kaysser-Kranich T.M., Palaniappan C., and Federoff H.J. Temporal evolution of mouse striatal gene expression following MPTP injury. Neurobiol Aging 26 (2005) 765-775
92. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstrale M., Laurila E., Houstis N., Daly M.J., Patterson N., Mesirov J.P., Golub T.R., Tamayo P., Spiegelman B., Lander E.S., Hirschhorn J.N., Altshuler D., and Groop L.C. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34 (2003) 267-273
93. Morgan J.I., Cohen D.R., Hempstead J.L., and Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science 237 (1987) 192-197
94. Morgan J.I., and Curran T. Stimulus-transcription coupling in neurons: role of cellular immediate-early genes. Trends Neurosci 12 (1989) 459-462
95. Murakami T., Shoji M., Imai Y., Inoue H., Kawarabayashi T., Matsubara E., Harigaya Y., Sasaki A., Takahashi R., and Abe K. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol 55 (2004) 439-442
96. Nagatsu T., Mogi M., Ichinose H., and Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl (2000) 143-151
97. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 11 (2005) 999-1016
98. Nurmi E., Ruottinen H.M., Bergman J., Haaparanta M., Solin O., Sonninen P., and Rinne J.O. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord 16 (2001) 608-615
99. O'Callaghan J.P., and Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270 (1994) 741-751
100. O'Reilly M.A. Redox activation of p21Cip1/WAF1/Sdi1: a multifunctional regulator of cell survival and death. Antioxid Redox Signal 7 (2005) 108-118
101. Ou Y.H., Chung P.H., Hsu F.F., Sun T.P., Chang W.Y., and Shieh S.Y. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J 26 (2007) 3968-3980
102. Oyake T., Itoh K., Motohashi H., Hayashi N., Hoshino H., Nishizawa M., Yamamoto M., and Igarashi K. Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16 (1996) 6083-6095
103. Pattarini R., Smeyne R.J., and Morgan J.I. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease. Neuroscience 145 (2007) 654-668
104. Perez-Otano I., Mandelzys A., and Morgan J.I. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res 53 (1998) 41-52
105. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., Chen F., Gu Y., Hasegawa H., Salehi-Rad S., Wang L., Rogaeva E., Fraser P., Robinson B., St George-Hyslop P., and Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem 280 (2005) 34025-34032
106. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
107. Pridgeon J.W., Olzmann J.A., Chin L.S., and Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5 (2007) e172
108. Przedborski S., and Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 991 (2003) 189-198
109. Qian Y.M., Qin X., Miwa T., Sun X., Halperin J.A., and Song W.C. Identification and functional characterization of a new gene encoding the mouse terminal complement inhibitor CD59. J Immunol 165 (2000) 2528-2534
110. Quackenbush J. Computational analysis of microarray data. Nat Rev 2 (2001) 418-427
111. Reichard J.F., Motz G.T., and Puga A. Heme oxygenase-1 induction by NRF2 requires inactivation of the transcriptional repressor BACH1. Nucleic Acids Res (2007) in press
112. Rescher U., and Gerke V. S100A10/p11: family, friends and functions. Pflugers Arch 455 (2008) 575-582
113. Rety S., Sopkova J., Renouard M., Osterloh D., Gerke V., Tabaries S., Russo-Marie F., and Lewit-Bentley A. The crystal structure of a complex of p11 with the annexin II N-terminal peptide. Nat Struct Biol 6 (1999) 89-95
114. Rinne O.J., Nurmi E., Ruottinen H.M., Bergman J., Eskola O., and Solin O. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 40 (2001) 193-200
115. Rocke D.M., and Durbin B. Approximate variance-stabilizing transformations for gene-expression microarray data. Bioinformatics 19 (2003) 966-972
116. Rollema H., Kuhr W.G., Kranenborg G., De Vries J., and Van den Berg C. MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J Pharmacol Exp Ther 245 (1988) 858-866
117. Santamaria-Kisiel L., Rintala-Dempsey A.C., and Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396 (2006) 201-214
118. Schapira A.H. Etiology of Parkinson's disease. Neurology 66 (2006) S10-S23
119. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7 (2008) 97-109
120. Schmidt J., Mertz K., and Morgan J.I. Regulation of heme oxygenase-1 expression by dopamine in cultured C6 glioma and primary astrocytes. Brain Res Brain Res Rev 73 (1999) 50-59
121. Schoenebeck B., Bader V., Zhu X.R., Schmitz B., Lubbert H., and Stichel C.C. Sgk1, a cell survival response in neurodegenerative diseases. Mol Cell Neurosci 30 (2005) 249-264
122. Schreiber S.S., Tocco G., Shors T.J., and Thompson R.F. Activation of immediate early genes after acute stress. Neuroreport 2 (1991) 17-20
123. Scolding N.J., Frith S., Linington C., Morgan B.P., Campbell A.K., and Compston D.A. Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol 22 (1989) 169-176
124. Serdobova I., Pla M., Reichenbach P., Sperisen P., Ghysdael J., Wilson A., Freeman J., and Nabholz M. Elf-1 contributes to the function of the complex interleukin (IL)-2-responsive enhancer in the mouse IL-2 receptor alpha gene. J Exp Med 185 (1997) 1211-1221
125. Shen Y.Q., Hebert G., Lin L.Y., Luo Y.L., Moze E., Li K.S., and Neveu P.J. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. J Neuroimmunol 158 (2005) 14-25
126. Shim K.S., Rosner M., Freilinger A., Lubec G., and Hengstschlager M. Bach2 is involved in neuronal differentiation of N1E-115 neuroblastoma cells. Exp Cell Res 312 (2006) 2264-2278
127. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res 134 (2005) 57-66
128. Smith T.S., Trimmer P.A., Khan S.M., Tinklepaugh D.L., and Bennett Jr. J.P. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment. Brain Res 765 (1997) 189-197
129. Sriram K., Benkovic S.A., Hebert M.A., Miller D.B., and O'Callaghan J.P. Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key signaling pathway for astrogliosis in vivo?. J Biol Chem 279 (2004) 19936-19947
130. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J 20 (2006) 670-682
131. Stichel C.C., Augustin M., Kuhn K., Zhu X.R., Engels P., Ullmer C., and Lubbert H. Parkin expression in the adult mouse brain. Eur J Neurosci 12 (2000) 4181-4194
132. Stichel C.C., Schoenebeck B., Foguet M., Siebertz B., Bader V., Zhu X.R., and Lubbert H. sgk1, A member of an RNA cluster associated with cell death in a model of Parkinson's disease. Eur J Neurosci 21 (2005) 301-316
133. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., and Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) in press
134. Subramanian A., Kuehn H., Gould J., Tamayo P., and Mesirov J.P. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics 23 (2007) 3251-3253
135. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., and Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102 (2005) 15545-15550
136. Sundstrom E., Stromberg I., Tsutsumi T., Olson L., and Jonsson G. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405 (1987) 26-38
137. Tan E.K., Yew K., Chua E., Puvan K., Shen H., Lee E., Puong K.Y., Zhao Y., Pavanni R., Wong M.C., Jamora D., de Silva D., Moe K.T., Woon F.P., Yuen Y., and Tan L. PINK1 mutations in sporadic early-onset Parkinson's disease. Mov Disord 21 (2006) 789-793
138. Taymans J.M., Van den Haute C., and Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98 (2006) 951-961
139. 2+/phospholipid-binding proteins, annexin family. J Biol Chem 267 (1992) 8919-8924
140. Unoki M., and Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20 (2001) 4457-4465
141. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
142. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98 (2001) 2837-2842
143. Wakabayashi K., Tanji K., Mori F., and Takahashi H. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology 27 (2007) 494-506
144. Wilms H., Zecca L., Rosenstiel P., Sievers J., Deuschl G., and Lucius R. Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des 13 (2007) 1925-1928
145. Wood-Kaczmar A., Gandhi S., and Wood N.W. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12 (2006) 521-528
146. Xie X., Lu J., Kulbokas E.J., Golub T.R., Mootha V., Lindblad-Toh K., Lander E.S., and Kellis M. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature 434 (2005) 338-345
147. Yuan Y., Jin J., Yang B., Zhang W., Hu J., Zhang Y., and Chen N.H. Overexpressed Alpha-Synuclein Regulated the Nuclear Factor-kappaB Signal Pathway. Cell Mol Neurobiol (2007) in press
148. Zeng Z., Su K., Kyaw H., and Li Y. A novel endothelin receptor type-B-like gene enriched in the brain. Biochem Biophys Res Commun 233 (1997) 559-567
149. Zhang X.L., Zhang D., Michel F.J., Blum J.L., Simmen F.A., and Simmen R.C. Selective interactions of Klf9/basic transcription element-binding protein with progesterone receptor isoforms A and B determine transcriptional activity of progesterone-responsive genes in endometrial epithelial cells. J Biol Chem 278 (2003) 21474-21482
150. Zhou H., Falkenburger B.H., Schulz J.B., Tieu K., Xu Z., and Xia X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3 (2007) 242-250